By staff writers

August 9, 2017 -- Medical device company Stimwave Technologies has received U.S. Food and Drug Administration (FDA) for StimQ, a wireless MR-conditional neuromodulation stimulator device for treating chronic peripheral nerve pain.

The system pinpoints stimulation directly to the affected peripheral nerves using a multielectrode programmable device, according to the firm. It also allows patients to receive full-body MRI exams without having to remove implants, Stimwave said.

Copyright © 2017

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking